Crossover Blinded Trial of Cell Therapy Versus Placebo in COPD
Withdrawn before enrolling · Not applicable · Has a placebo group
Conditions studied: COPD, Emphysema or COPD, Chronic Bronchitis
In brief
The aim of this randomized, controlled crossover designed study is to compare the outcomes of receiving autologous, adult stem cells versus placebo among participants with chronic obstructive pulmonary disease (COPD). The study is limited to self-funded participants with a diagnosis of COPD. The study, along with others at the Lung Institute, have received full review and approval of an Institutional Review Board.
Key facts
- Study ID
- NCT03228121
- Run by
- Lung Institute
- People needed
- 0
- Starts
- 2017-04-24
- Expected to finish
- 2018-09-11
- Last updated by the study team
- 2018-09-13
Who can join
Age: 16 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Patients are included in treatment by self-referral and after consultation with a designated patient coordinator who determines initial eligibility, and then by the clinic nurse practitioner or physician of Lung Institute who determines final eligibility for inclusion. Patients must be diagnosed with chronic obstructive pulmonary disease (COPD) and be able to travel to the Dallas clinic location.
You may not qualify if…
- Patients who are unable to provide informed consent, pregnant patients, prisoners, non-English speakers, patients with a history of cancer within the past 5 years, patients with active tuberculosis or pneumonia. Patients without a documented COPD diagnosis are excluded.
Where it is running
- Lung Institute Dallas — Dallas, Texas, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.